DAYBUE receives marketing authorization in Canada
Released
Released
Announcement PDF
Neuren (NEU) – ASX Announcement
17 October 2024
DAYBUE™ (trofinetide) receives marketing authorization in Canada
Highlights:
•
Acadia Pharmaceuticals announces Health Canada approval of DAYBUE™ (trofinetide) for the
treatment of Rett syndrome in adult and pediatric patients two years of age and older under the
Priority Review process
•
First and only approved treatment for Rett syndrome in Canada
•
Potential sales in Canada will be added to US sales for calculation of Neuren’s royalties and sales
milestone payments
Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) today announced that its partner Acadia
Pharmaceuticals (NASDAQ: ACAD) received Health Canada approval of DAYBUE™ (trofinetide) for the
treatment of Rett syndrome in adult and pediatric patients two years of age and older under the Priority
Review process. This makes it the first and only drug approved in Canada for the treatment of Rett
syndrome.
In Canada, prevalence of Rett syndrome is estimated to be 600 to 900 patients. 1 In Canada, DAYBUE is
indicated for the treatment of Rett syndrome in adults and pediatric patients two years of age and older
and weighing at least 9 kg.
For further details please refer to Acadia’s announcement https://acadia.com/media/newsreleases/acadia-pharmaceuticals-announces-health-canada-approval-of-daybue-trofinetide-for-thetreatment-of-rett-syndrome/
Neuren CEO Jon Pilcher commented: “We are excited to see this first approval outside the United States,
which is a significant milestone in the ongoing program to expand access to DAYBUE.”
Canada is included as part of the North America region under Neuren’s agreement with Acadia. Potential
sales in Canada will be added to US sales for calculation of Neuren’s royalties and sales milestone
payments.
Tiered Royalty Rates (% of net sales)2
Sales Milestones payments
Annual Net Sales
Rates
Net Sales in one calendar year
US$m
≤US$250m
10%
≥US$250m
50
>US$250m, ≤US$500m
12%
≥US$500m
50
>US$500m, ≤US$750m
14%
≥US$750m
100
>US$750m
15%
≥US$1bn
150
1 Acadia estimates
2 Royalty rates payable on the portion of annual net sales that fall within the applicable range. Each sales milestone payment is payable once
only.
1 of 2
About Neuren
Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in
early childhood and have no or limited approved treatment options. Recognising the urgent unmet
need, all programs have been granted “orphan drug” designation in the United States. Orphan drug
designation provides incentives to encourage development of therapies for rare and serious diseases.
DAYBUE™ (trofinetide) is approved by the US Food and Drug Administration (FDA) for the treatment of
Rett syndrome in adult and pediatric patients two years of age and older. Neuren has granted an
exclusive worldwide licence to Acadia Pharmaceuticals Inc. for the development and commercialisation
of trofinetide.
Neuren’s second drug candidate, NNZ-2591, is in Phase 2 development for multiple neurodevelopmental
disorders, with positive results achieved in Phase 2 clinical trials in Phelan-McDermid syndrome, Pitt
Hopkins syndrome and Angelman syndrome.
Contact:
investorrelations@neurenpharma.com
Jon Pilcher, CEO: +61 438 422 271
ASX Listing Rules information
This announcement was authorized to be given to the ASX by the board of directors of Neuren
Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124
Forward-looking Statements
This announcement contains forward-looking statements that are subject to risks and uncertainties. Such
statements involve known and unknown risks and important factors that may cause the actual results,
performance or achievements of Neuren to be materially different from the statements in this
announcement.
2 of 2
Share your feedback
Discover